September 16th, 2021 | 11:58 CEST
Siemens Healthineers, PuriflOH, Fresenius, Novavax - Focusing on health!
Table of contents:
Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.
Siemens Healthineers - With momentum into the DAX
Siemens Healthineers AG is a 2018 spin-off of Siemens AG and is currently listed on the MDAX. With the index changeover in mid-September, the Company will be represented in the DAX 40. The Company's core areas include imaging for diagnostics and therapy, laboratory diagnostics, digital healthcare services and hospital management.
The Erlangen-based Company offers systems for X-ray, CT and magnetic resonance imaging and blood and urine tests. The Company's medical equipment and clinical information technology are used by hospitals and research laboratories and are applied in various subspecialties such as cardiology, oncology and neurology.
Medical systems suppliers are in demand everywhere, not least because of the pandemic. The public has learned during the crisis that a functioning healthcare system is more than a cost factor. In the current fiscal year 2020/21, Siemens Healthineers had already raised its forecast several times, partly due to the high demand for corona tests. The Company now plans to present its new medium-term targets at the upcoming Capital Markets Day in November.
After the costly acquisition of US cancer therapy specialist Varian, we think the balance sheet needs to catch its breath because the integration of US units does not always go smoothly. The Siemens Healthineers share has performed well and is up more than 50% on a 12-month basis. The Company's positioning is good, but a DAX listing is no guarantee for further share price increases.
PuriflOH Ltd. - Air purification in focus
In the COVID-19 pandemic, air and building cleaning are of particular importance. Aerosols should dissipate quickly, and contact surfaces in public buildings must be cleared of germs and biological contaminants. PuriflOH is an Australian Company that has addressed these issues and is also active through a US subsidiary based in Detroit.
The Company's primary focus is on innovative solutions for cleaning the air, water and contact surfaces in public and private areas. Such measures are essential for the economy, especially in government, business and industrial areas where many people work in confined spaces. PuriflOH's systems are already patented, and it currently has a two-stage process technology specially adapted for equalizing biological and chemical contaminants in the air.
Expenditure on research and development in recent years is now paying off, as the current solutions are scalable to any degree, meaning that profit margins increase with each order. The Company is currently looking for suitable IP licensing partners for industrial-scale production to sustain the business. Of course, investments are also needed in sales. The Company is already in successful talks with air purification specialists and water treatment companies on the commercialization side. The annual figures for 2020/21 still show a loss of AUD 3.1 million, but this should mean that most of the market entry expenditures have already been made.
With a market capitalization of AUD 42.6 million, the technology company is currently still moderately valued. The upcoming government health measures alone will likely generate substantial orders for corresponding technical solutions in the next few years. With its patented systems, PuriflOH is ready for this and can grow accordingly.
Fresenius - Things are not going quite so well
Fresenius has not been able to get off the ground despite many buy recommendations. Despite new highs for the year on the DAX, the health care specialist has recently lost around 7%. Corona-related losses at the dialysis subsidiary Fresenius Medical Care (FMC) continued to weigh on the second quarter. The Company's original assumption that the general conditions are likely to improve in the current half of the year is increasingly in jeopardy from today's perspective.
Although the slightly raised forecasts suggest growth in adjusted earnings in the low single-digit percentage range, the pandemic could again lead to uncertainties in the fall. At FMC, earnings in the past quarter of the year had slumped much more sharply than expected. The parent company had announced a package of measures in the spring, which should bring improvements in earnings of at least EUR 100 million per year by 2023. We do not yet believe that the share price will turn around sustainably in this environment.
Novavax - The vaccine is coming in the fall
Things are now getting exciting at Novavax. The highly hyped stock will launch the first combined Corona influenza vaccine in the fall. Currently, participants have been recruited for the Phase I/II trial, which will evaluate the safety and immunogenicity of a combination vaccine made up of the Novavax and Covid-19 seasonal influenza vaccines. The clinical trial combines the recombinant protein-based vaccine candidates NVX-CoV2373 and NanoFlu and the patented saponin-based Matrix-M adjuvant into a single formulation.
The combination of these two vaccines, which individually have provided excellent results with favorable safety and tolerability profiles, may result in greater efficacy for the healthcare system and achieve a high level of protection against Covid-19 and influenza with a single treatment. Participants in the current study must have either been previously infected with the SARS-CoV-2 virus or vaccinated for at least eight weeks before enrollment.
If the approval is successful, the willingness of many people with current reservations to be vaccinated should get another boost. We expect that the share will then also leave its current consolidation phase and make significant gains. The market capitalization is currently USD 17 billion, which is not too expensive for potential sales of over USD 5 billion in 2022.
The healthcare sector is particularly challenged in the current pandemic. In the case of Siemens Healthineers, the numbers improved by leaps and bounds; for Fresenius, the virus was more of a damper. For Novavax and PuriflOH, the general conditions currently look very good. PuriflOH is still small, but scaling up sales can bring significant momentum here.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.